MycoMedica Life Sciences, PBC, a new company focused on developing and delivering fungi-based therapeutic drugs to prevent and treat psychiatric and neurological disorders, raised $60 million in funding.
The round was led by Obvious Ventures, True Ventures and Kittyhawk Ventures.
The proceeds from the financing will be used to advance the company’s next stage of operations on the path to FDA approval for an Investigational New Drug Application (IND) – pre-clinical research and initial clinical trials of the Stamets Stack.
Led by Paul Stamets, CEO and Founder, and Sanjay Dubé M.D., President and Chief Medical Officer, MycoMedica has developed the Stamets Stack, which uses a novel combination of ingredients – not found together in nature – to unlock the potential effectiveness of psilocybin in the prevention and treatment of psychiatric and neurological disorders. The company’s initial research is centered on microdosing, which also allows for greater patient affordability and accessibility.
FinSMEs
02/06/2022